Medical Access in Australia

Psilocybine access is limited to treatment-resistant depression when a specialist psychiatrist is authorised by TGA under the Authorised Prescriber framework, with HREC support and supervised dosing in a clinical setting. There is no ARTG-approved psilocybine product, and patients cannot take the medicine home. DVA can fund psychedelic-assisted psychotherapy for eligible veterans under strict prior criteria, but that does not create a general PBS or private-insurance pathway. [1]TGA psychiatrist access guidance [2]TGA consumer access guidance [3]DVA PAP provider guidance

MDMA access is limited to PTSD when supplied by an authorised specialist psychiatrist under the Authorised Prescriber pathway, or within approved clinical trials. Importation and supply remain controlled through Office of Drug Control licences and permits. DVA can fund MDMA-assisted psychotherapy for eligible veterans, with no retrospective reimbursement for self-funded treatment. [1]TGA psychiatrist access guidance [2]Office of Drug Control MDMA and psilocybine regulation [3]DVA PAP patient guidance [4]DVA PAP provider guidance

Spravato is the clearest subsidised route. It is TGA-registered for treatment-resistant depression and the PBS Medicine Status page records PBS listing from 1 May 2025. Access remains indication- and rule-limited, but it is a mainstream reimbursement pathway in a way MDMA and psilocybine are not. [1]TGA Spravato AusPMD [2]PBS esketamine medicine status [3]PBS overview

Ketamine is used off-label in Australian psychiatric practice and has local evidence in treatment-resistant depression, including the KADS repeated subcutaneous-ketamine trial. It is not the same as PBS-listed Spravato, and reimbursement depends on setting, insurer, hospital billing and patient circumstances rather than a dedicated national psychiatric ketamine subsidy. [1]RANZCP ketamine practice guidance [2]KADS ketamine trial [3]KADS cognitive outcomes paper [4]TGA ketamine and esketamine scheduling notice

DMT does not have a routine medical access route in Australia. The reviewed sources show local phase 1 research with DMT-harmala, but the Authorised Prescriber pathway discussed by TGA applies to MDMA and psilocybine, not DMT. [1]DMT-harmala phase 1 study [2]TGA consumer access guidance

5-MeO-DMT has no authorised routine medical use in Australia. Australian sites appeared in the BPL-003 development programme, but a trial registry entry is not a prescribing or reimbursement pathway. [1]ClinicalTrials.gov NCT05870540 [2]TGA consumer access guidance

No authorised or reimbursed medical pathway for ibogaine was verified in the reviewed Australian primary sources. It should be treated as outside routine medical access unless a specific clinical trial, import permission and ethics-approved protocol can be identified. [1]Poisons Standard June 2025

No authorised or reimbursed medical pathway for ayahuasca was verified in the reviewed Australian primary sources. Because DMT-containing preparations raise separate controlled-substance questions, any claim of lawful access should be checked against current scheduling, import controls and trial approvals. [1]Poisons Standard June 2025

No authorised or reimbursed medical pathway for mescaline was verified in the reviewed Australian primary sources. The current therapeutic access architecture is focused on MDMA, psilocybine, esketamine and off-label ketamine rather than mescaline. [1]Poisons Standard June 2025 [2]TGA consumer access guidance

No authorised or reimbursed medical pathway for 2C compounds was verified in the reviewed Australian primary sources. Any Australian clinical use claim would need a trial registration and regulator-authorised supply route. [1]Poisons Standard June 2025